Fusion proteins having a toxin and cancer marker, nanoparticles, and uses related thereto
AssigneeEmory University
InventorsLily Yang, Xiangxue Guo, Hui Mao, Wei Chen
Life of this patent
Estimating the term…
Abstract
This disclosure relates to nanoparticles coated with fusion proteins comprising a domain that binds a cancer marker and a domain comprising a toxic polypeptide. In certain embodiments, the targeted cancer marker is urokinase plasminogen activator receptor (uPAR) insulin-like growth factor 1 receptor (IGF1R), EGFR, HER2, and/or other member of the ErbB family of receptors. In certain embodiments, the molecule that binds a cancer marker is an amino terminal fragment of uPA or variant capable of binding uPAR and/or IGF1 or variant capable of binding IGF1R. In certain embodiments, the toxic polypeptide is a bacterial exotoxin.
Claims12
A nanoparticle coated with a fusion peptide comprising NCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQHCEIDKSKGGGGSGAPEGGSLAALTAH QACHLPLETFTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQVDQVIRNALASPG SGGDLGEAIREQPEQARLALTLAAAESERFVRQGTGNDEAGAANGPADSGDALLERNY PTGAEFLGDGGDVSFSTRGTQNWTVERLLQAHROLEERGYFVGYHGTFLEAAQSIVFG GVRARSQDLDAIWRGFYIAGDPALAYGYAQDQEPDARGRIRNGALLRVYVPRSSLPGF YRTSLTLAAPEAAGEVERLIGHPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAIPT DPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPPKDEL (SEQ ID NO:
- 1), and wherein the nanoparticle is further coated with a recombinant IGF1 peptide that binds insulin-like growth factor 1 receptor.
A nucleic acid sequence comprising a sequence encoding the fusion protein having SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.